Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of astragaloside IV in inhibiting local inflammatory response and treating arterial restenosis

An astragaloside IV, inflammatory reaction technology, applied in the directions of anti-inflammatory agents, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve the problem that the mechanism of occurrence is not fully understood and the like

Pending Publication Date: 2020-06-09
AFFILIATED HOSPITAL OF JINING MEDICAL UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A large number of clinical and experimental studies have been done at home and abroad, but the mechanism of restenosis is still not fully understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astragaloside IV in inhibiting local inflammatory response and treating arterial restenosis
  • Application of astragaloside IV in inhibiting local inflammatory response and treating arterial restenosis
  • Application of astragaloside IV in inhibiting local inflammatory response and treating arterial restenosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] 1. Main instruments and consumables:

[0029]-80°C ultra-low temperature refrigerator, liquid nitrogen, autoclave, Eppendorf micropipette, Image Quant LAS500 imager, microplate reader, electrophoresis apparatus, vortex mixer, high-speed cold centrifuge, ultra-clean bench, electronic balance , balloon catheter

[0030] 2. Main reagents:

[0031] AS-IV (Beijing Apprise Technology Company), CD3 immunohistochemistry kit, CD68 immunohistochemistry kit, Ki67 immunohistochemistry kit, chloral hydrate, sodium carboxymethylcellulose (Beijing Dingguo Biotechnology Co., Ltd. company), PCNA, a-SMA (Abcam Biological Company of the United States), ICAM-1, β-actin, goat anti-rabbit secondary antibody, BSA (Wuhan Aibotek Biological Company).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of astragaloside IV (AS-IV) in inhibiting local inflammatory response and treating arterial restenosis, and relates to the technical field of novel applications of traditional Chinese medicines. According to the invention, a rat carotid artery balloon injury model is established to simulate vascular intimal injury after percutaneous coronary intervention (PCI)surgery, and the inhibitory effect of the AS-IV on proliferation of VSMCs and inflammation in vivo is clarified, so that a novel safe and effective solution is provided for prevention and treatment of restenosis after the PCI surgery.

Description

technical field [0001] The invention belongs to the technical field of new uses of traditional Chinese medicines, and specifically relates to the application of astragaloside IV in inhibiting local inflammatory reactions and treating arterial restenosis. Background technique [0002] There are 290 million people suffering from cardiovascular diseases in my country, including about 11 million people with coronary heart disease (Coronary Heart Disease, CHD). The popularity of PCI technology is a major historical breakthrough in the treatment of CHD, and its popularity has significantly improved the prognosis of CHD patients. However, the ensuing complication of in-stent restenosis (In-stent restenosis, ISR) seriously restricts the application of this technique. ISR is now generally accepted to mean that the net loss rate of coronary angiography within 6 to 9 months after stent implantation is ≥50%. The clinical incidence of ISR after bare metal stent implantation is 20%-35%....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P9/10A61P29/00
CPCA61K31/7048A61P9/10A61P29/00
Inventor 张金国张斌李友乾尉希清申程别庆丽陈雪英张延春仲媛媛
Owner AFFILIATED HOSPITAL OF JINING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com